To analyze the clinical efficacy and safety of salmeterol fluticasone propionate combined with cetirizine hydrochloride and montelukast sodium tablet in the treatment of children with cough variant asthma.

The children with cough variant asthma were divided into control group and treatment group by random number table method. The control group was treated with oral montelukast sodium chewable tablets and cetirizine hydrochloride oral solution, both 10 mg every time, qd; the treatment group was treated with salmeterol fluticasone propionate inhalation powder inhalation, 1 inhalation/time, bid on the basis of the control group. Children in both groups continued treatment for 3 weeks. The clinical efficacy, pulmonary function, airway reaction status, immune function index, inflammatory index and adverse drug reactions were compared between the two groups.

In the treatment group, 50 cases were enrolled, 1 case was lost, and 49 cases were finally included in the statistical analysis. In the control group, 52 cases were enrolled, 3 cases were lost, and finally 49 cases were included in the statistical analysis. After treatment, the total effective rate of the control group and the treatment group were 77.55% (38 cases/49 cases) and 93.88% (46 cases/49 cases), respectively, and the difference were statistically significant (P<0.05). After treatment, the maximum expiratory flow were (4.68±0.56) and (5.07±0.62) L·s^-1 in the control and treatment groups; the vital capacity were (0.98±0.05) and (1.02±0.07) L; the forced expiratory volume in the first second were (75.72±7.24)% and (80.03±8.36)%; the forced vital capacity were (75.49±7.68)% and (79.97±6.72)%; the initial airway resistance were (7.33±0.75) and (7.01±0.73) cm H₂O·L^-1·s^-1; the minimum induced cumulative dose were (1.89±0.14) and (2.01 ± 0.25) mg·L^-1; the 35th percentile of specific airway conduction decrease were (5.24±0.52)% and (5.59±0.68)%. There were statistically significant differences in the above indexes between the treatment group and the control group (P<0.05, P<0.01, P<0.001). The adverse drug reactions of the control group and the treatment group were headache, palpitation and sleep difficulty, and the incidence of the total adverse drug reactions of the treatment group and the control group were 6.12% (3 cases /49 cases) and 12.24% (6 cases /49 cases), respectively, with no statistical significance (P>0.05).

Salmeterol fluticasone propionate, cetirizine hydrochloride and montelukast sodium tablet are effective and safe in the treatment of children with cough variant asthma.